TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 to 75 years of age~* Advanced and/or metastatic gastric cancer with at least 1 measurable lesion~Exclusion Criteria:~* Uncontrolled infection~* Evidence of central nervous system (CNS) metastases~* History of other malignancy within the last 5 years, except cured basal cell cancer of the skin or cured in-situ cancer of the uterine cervix~* Radiation therapy or major surgery within 4 weeks of study drug~* Previous chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 5-Fluorouracil + Cisplatin (Type: ACTIVE_COMPARATOR): Participants will receive 5-FU in combination with cisplatin upto disease progression.
- Capecitabine + Cisplatin (Type: EXPERIMENTAL): Participants will receive capecitabine in combination with cisplatin upto disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female inpatients or outpatients, 10-17 years of age, who have not reached their 18th birthday prior to screening. Patient must weigh at least 20 kilograms (kg) at screening.~* Must meet diagnostic criteria for current major depressive episode of Bipolar I Disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Version (DSM-IV-TR) and confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime (K-SADS-PL)~* Patients entering the study will also be scored by the Children's Depression Rating Scale-Revised (CDRS-R) (entry score of greater than or equal to 40) as well as the adolescent-structured Young Mania Rating Scale (YMRS) (entry score of less than or equal to 15 with YMRS Item 1 \[elevated mood\] score less than equal to 2).~Exclusion Criteria:~* Patients will be excluded if they are, in the opinion of the investigator, actively suicidal~* Have an acute, serious or unstable medical condition~* Have clinically significant laboratory abnormalities~* Have had one or more seizures of unclear etiology~* Have a current or lifetime diagnosis of any of the following according to DSM-IV criteria: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Psychotic Disorder Not Otherwise Specified, Delirium of any type, Amnestic Disorder, any Substance-Induced Disorder, or any Psychotic Disorder due to a General Medical Condition, unless there is substantive reason to believe patient was misdiagnosed

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine/Fluoxetine Combination (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be aged between 6 months and 70 years old;~* Be with mono-infection confirmed laboratorial by P.falciparum;~* Having parasite count between 250/µl and 100000/µl;~* If female, not pregnant, confirmed by specific test;~* Being feverish or report having had fever (axillary temperature \>37.5°C or 99,5°F) in last 48 hours;~* Be able to receive oral medication;~* Demonstrate interest and facility to meet the schedule of visits and monitoring for 42 days;~* Agree to participate in the study by signature (or parents) of Consent Term;~* Do not show evidence of severe malnutrition: underweight 60% of the weight-standard, below-average height for age indicating malnutrition in the past and weight-height below the average indicating dietary current deficiencies (WHO, 2006);~* Do not show danger signals to severe malaria. Note: We will be careful to include individuals who have used quinine or quinidine recently (three days before), because the risk of toxicity due to interaction with mefloquine.~Exclusion Criteria:~* Present after inclusion, danger signs/symptoms for severe malaria as recommended by the WHO;~* Present after inclusion, laboratory evidence of mixed infection with another species of Plasmodium;~* Having a diagnosis of other acute infectious disease that courses with fever, such as acute respiratory infection, common viruses of childhood diarrhea, etc;~* Having a diagnosis of chronic co morbidities or severe disease such as cirrhosis, chronic renal failure or heart failure;~* Have a history of hypersensitivity to the components of the combination ASMQ.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- artesunate & mefloquine combination (Type: EXPERIMENTAL): ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to \<18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to \<9 kg = 1 tablet once daily for 3 days, 9 to \<18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
For FP Clinics:~Inclusion Criteria:~* All FP clinics that receive County-supplied FP products will be eligible to participate.~Exclusion Criteria:~* Any clinic that is expected to be closed during part or all of the SAIA intervention period will be excluded. Any FP clinic that was previously included in the FP HIV SAIA trial will be excluded.~FP clinic managers and staff:~Inclusion Criteria:~* Any FP clinic manager that is 18 years and older is eligible to be interviewed.~Exclusion Criteria:~* These clinic managers can be male or female.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
- Intervention with SAIA (Type: EXPERIMENTAL): Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olfactory Contributions to Sleep-dependent Food Craving

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 40 years old~* regular sleep schedule (average sleep duration of ≥7 h/night, habitual mid-sleep time 3-5 am \[deviation ≤2 h in daily mid-sleep time\], time in bed ≤9 h)~* right-handed~* fluent English speakers~Exclusion Criteria:~* history of significant cerebrovascular disease including (but not limited to) epilepsy, stroke, multiple sclerosis, meningitis~* body mass index (BMI) below 18.5 (underweight) or above 24.9 (overweight or obese)~* history of sleep disorder~* job with night shifts~* history of major head trauma with sustained loss of consciousness~* history of neurosurgery, ear-nose-throat (ENT) surgery, or cardiac surgery~* history of cardiac pacemaker or neurostimulator implantation~* history of significant medical illness including cardiovascular disease, diabetes, cancer, chronic obstructive pulmonary disease, severe asthma requiring hospitalization for treatment, renal insufficiency requiring dialysis, etc.~* history of major psychiatric disorder including major affective disorder, obsessive-compulsive disorder, schizophrenia~* claustrophobia~* history of significant food or non-food allergy, including latex, detergents, soaps~* presence of known smell, taste or ENT disorder~* history of sinusitis or allergic rhinitis~* history of alcoholism or consistent drug use~* current smoking~* current use of medications that affect alertness (e.g. barbiturates, benzodiazepines, cannabinoids, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, etc.)~* current pregnancy (or possible pregnancy)~* history of metal working, or injury with shrapnel or metal slivers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Sleep-Deprived first, then Non-Sleep Deprived (Type: EXPERIMENTAL): Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
- Non-Sleep Deprived first, then Sleep-deprived (Type: EXPERIMENTAL): Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 10-18 years of age (both inclusive)~* Genetically confirmed diagnosis of Prader-Willi Syndrome~* Determined to be in nutritional phase 3 by clinical assessment based on Miller et al, 2011~Exclusion Criteria:~* Known genetic, hormonal, or chromosomal cause of cognitive impairment other than Prader-Willi Syndrome~* Presence of currently active psychotic symptoms~* Presence of any cardiovascular disorders, epilepsy, frequent migraines or severe asthma~* Previous diagnosis of autism spectrum disorder by a qualified healthcare provider~* Prior or concomitant use of a selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI), antipsychotic medication, wakefulness-promoting drug, or thyroid hormone unless dosage has been stable ≥6 months at time of screening

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- FE 992097 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients and outpatients meeting the diagnostic criteria probable VaD established according to the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) （DSM-Ⅳ） and the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)were eligible to participate,~* diagnosis of mild to moderate vascular dementia;~* Chinese-speaking patients aged ≥45 and≤85 years old in both gender;~* weighing between 45 and 90kg;~* fully conscious;~* MMSE score of≤26 and ≥14;~* HIS score of ≥7;~* adequate vision and hearing ability to complete all study tests;~* with a stable caregiver.~Exclusion Criteria:~Patients will be excluded from the enrollment if they meet any of the followings:~* a medical history of other dementia types, like Alzheimer's disease, Parkinson's disease dementia, Huntington disease, Normal pressure hydrocephalus, et al;~* major depression (HAMD for 17 items\>17) or psychotic disorder;~* acute stage of cerebral hemorrhage or subarachnoid hemorrhage;~* hypothyroidism;~* drug or alcohol abuse;~* epilepsy history; myasthenia gravis history;~* severe cardiovascular disease(severe arrhythmia with heart rate≥100 or≤60 times per min, left bundle branch block, myocardial infarction within 3 months, systolic pressure≥180mmHg or ≤90mmHg);~* severe liver or kidney dysfunction (alanine aminotransferase\>60 IU/L, aspartate transaminase\>60 IU/L or serum creatinine \>266μmol/L);~* severe asthma or chronic obstructive pulmonary disease;~* gastrointestinal tract obstruction or severe peptic ulcer; glaucoma;~* administration of cholinesterase inhibitors, memantine or nimodipine in the last month;~* use of sympathomimetic agent, antihistamine drug, antianxiety drugs or tranquilizer within 48h before assessment;~* use of antipsychotic drugs within 72h before assessment;~* participation in other clinical trials; allergic history to any type of medication used in this study.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Tianzhi granule (Type: EXPERIMENTAL): Tianzhi granule and placebo identified to donepezil
- Donepezil (Type: ACTIVE_COMPARATOR): Donepezil and placebo identified to Tianzhi granule
- Placebo (Type: PLACEBO_COMPARATOR): Placebo identified toTianzhi granule and placebo identified to donepezil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years of age~* Male and female subjects~* Surgical sterilization~* Childbearing potential: beta HCG on study day~* Subjects with a body mass index of 25 or greater~Exclusion Criteria:~* Diabetes type 1 to type 2 as defined by a fasting glucose of 126 mg/dl or greater or the use of anti-diabetic medication~* Use of hormone replacement therapy~* Statin therapy~* In hypertensive subjects, a seated systolic blood pressure greater than 179 mmHg or a seated diastolic blood pressure greater than 110 mmHg or taking hypertensives~* Pregnancy/Breast Feeding~* Cardiovascular disease such as myocardial infarction with 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable) deep vein thrombosis, pulmonary embolism, second or three degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy~* Treatment with anticoagulants~* History of serious neurologic disease such as cerebral hemorrhage, stroke or transient ischemic attack~* Diagnosis of asthma~* Clinically significant gastrointestinal impairment that could interfere with drug absorption~* Hematocrit \<35%~* Hyperlipidemic fasting Total Cholesterol \>220mg/dl~* Impaired renal function (Serum creatinine \>1.5 mg/dl)~* History or presence of immunological or hematological disorders~* Any underlying or acute disease requiring regular medication which could possible pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult~* Impaired hepatic function (Serum glutamic oxaloacetic transaminase, serum glutamate pyruvate transaminase \> 60)~* Treatment with chronic systemic glucocorticoid therapy (more than 7 days in 1 month)~* Treatment with lithium salts~* History of Alcohol or drug abuse~* Treatment with any investigational drug 1 month preceding study~* Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study~* Inability to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Control (bradykinin infusion) (Type: EXPERIMENTAL): Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
- L-NMMA + bradykinin (Type: EXPERIMENTAL): N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
- Isosorbide + L-NMMA + bradykinin (Type: EXPERIMENTAL): Isosorbide (NO donor)
- Sildenafil + L-NMMA + bradykinin (Type: EXPERIMENTAL): Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female participants 60 years of age and older at the time of consent.~* Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. (For adults 60 through 64 years of age to be enrolled at Japan sites: Participants must have a preexisting chronic stable disease with an elevated risk for pneumococcal disease.)~Exclusion criteria:~* History of microbiologically proven invasive disease caused by S pneumoniae.~* Serious chronic disorder, including metastatic malignancy, severe COPD requiring supplemental oxygen, end-stage renal disease with or without dialysis, cirrhosis of the liver, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.~* Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 20vPnC/Saline (Type: EXPERIMENTAL): 20vPnC and saline
- 13vPnC/PPSV23 (Type: ACTIVE_COMPARATOR): 13vPnC and PPSV23

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who satisfy both of the following diagnostic criteria:~  1. Diagnosis of Dementia due to Alzheimer's Disease according to DSM-5.~ 2. Diagnosis of Probable Alzheimer's Disease according to NINCDS-ADRDA.~* Hospitalized patients or care facility patients or care at home patients~* Patients with an MMSE score of 1 to 22~* Patients who have the agitation defined according to the Consensus provisional definition of agitation in cognitive disorders from the International Psychogeriatric Association (IPA)~Exclusion Criteria:~* Patients who have dementia other than dementia of the Alzheimer's type~* Patients diagnosed with delirium between 30 days before the screening examination and baseline evaluation according to DSM-5.~* Patients diagnosed with any of the following disorders according to DSM-5:~  * Schizophrenia spectrum and other psychotic disorders~ * Bipolar and related disorders~ * Major depressive disorder

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole, 1mg/day (Type: EXPERIMENTAL): Drug: 1mg/day Once daily for 10 weeks
- Brexpiprazole, 2mg/day (Type: EXPERIMENTAL): Drug: 2mg/day Once daily for 10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Placebo (0mg/day) Once daily for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete